Acalabrutinib based drugs

Acalabrutinib is an anti-cancer medication, a second-generation selective Bruton's tyrosine kinase (BTK) inhibitor. It blocks the signaling pathways required for the survival and proliferation of malignant B-cells. It is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), including those who have received prior therapy.